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0022-2836 Crown Copyright © 2011 PubThe adenosine A2A receptor (A2AR) is a G-protein-coupled receptor that
plays a key role in transmembrane signalling mediated by the agonist
adenosine. The structure of A2AR was determined recently in an antagonist-
bound conformation, which was facilitated by the T4 lysozyme fusion in
cytoplasmic loop 3 and the considerable stabilisation conferred on the
receptor by the bound inverse agonist ZM241385. Unfortunately, the natural
agonist adenosine does not sufficiently stabilise the receptor for the
formation of diffraction-quality crystals. As a first step towards determining
the structure of A2AR bound to an agonist, the receptor was thermostabilised
by systematic mutagenesis in the presence of the bound agonist [3H]5'-N-
ethylcarboxamidoadenosine (NECA). Four thermostabilisingmutations were
identified thatwhen combined togivemutantA2AR-GL26, conferred a greater
than 200-fold decrease in its rate of unfolding compared to the wild-type
receptor. Pharmacological analysis suggested that A2AR-GL26 is stabilised in
an agonist-bound conformation because antagonists bind with up to 320-fold
decreased affinity. None of the thermostabilising mutations are in the
ZM241385 binding pocket, suggesting that the mutations affect ligand
binding by altering the conformation of the receptor rather than through
direct interactions with ligands. A2AR-GL26 shows considerable stability in
short-chain detergents, which has allowed its purification and crystallisation.
Crown Copyright © 2011 Published by Elsevier Ltd. Open access under CC BY license.Introduction
G-protein-coupled receptors (GPCRs) are the
largest superfamily of transmembrane receptors
with more than 800 members found in humans.1ress:
tein-coupled receptor;
e; β1AR, β1
egion; DM, n-decyl-β-
amster ovary;
ediaminetetraacetic
ild type;
ide; NECA,
lished by Elsevier Ltd. Open They are key proteins in human physiology because
they are the receptors for a wide variety of signalling
molecules (agonists) such as hormones, neurotrans-
mitters, lipids and nucleotides. Agonist binding to
GPCRs causes a conformational change that allows
coupling of either G proteins or β-arrestin and their
subsequent activation,2,3 resulting in increased
concentrations of intracellular second messengers
such as cAMP and Ca2+. The pivotal role of GPCRs
in intercellular communication makes them impor-
tant targets for the development of drugs.4,5
Understanding how different classes of ligands
(e.g., agonist, partial agonist, or inverse agonist)
bind to receptors and how they affect the confor-
mation of the receptor has been the goal of research
for many decades. Recent successes in the structure
determination of hormone-binding GPCRs haveaccess under CC BY license.
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receptors.6–11 In addition, recent structures of the β1
adrenoceptor (β1AR) and β2 adrenoceptor bound to
agonists have given us the first insights12–14 into
how agonists increase the probability of a receptor
being in the R⁎ state (G-protein-coupling conforma-
tion) as opposed to the inverse agonist state R (G
proteins unable to be activated).
Extracellular adenosine influences cellular func-
tion throughout the body, particular during
cellular stresses such as anoxia, but in the central
nervous system, it functions as a ubiquitous
neuromodulator.15 There are four adenosine re-
ceptors found in humans, A1, A2A, A2B and A3,
which belong to the GPCR family A. The A1, A2A
and A2B receptors are well known for being
inhibited by the antagonist caffeine.16 Adenosine
receptors are implicated in the pathophysiology of
many neurological disorders such as Parkinson's
disease, Huntington's disease as well as ischemia
(cerebral and cardiac) and inflammatory and im-
mune diseases.17,18 The adenosine A2A receptor
(A2AR) is therefore a potential target for treating
many diseases, with the most advanced drug,
preladenant, currently in phase III clinical trials for
the treatment of Parkinson's disease.19
A structure of A2AR has been determined with the
inverse agonist ZM241385 bound.8 The structure
consisted of a receptor T4 lysozyme (T4L) fusion
protein crystallised in lipidic cubic phase. Intracel-
lular loop 3 in GPCRs has variable length and may
be flexible before coupling to the G protein.
Engineering of T4L into this loop produced a
chimaeric receptor, A2A-T4L, which retains its
ability to bind both agonists and antagonists,
although this modified receptor binds agonists
with higher affinity compared to wild-type (WT)
A2AR;
8 thus, its conformation may be slightly biased
towards the agonist-bound state. A2A-T4L was
crystallised in the presence of the high-affinity
inverse agonist ZM241385 to help stabilise the
detergent-solubilised A2AR. With its pharmacology
favouring agonist binding in comparison to the WT
receptor yet being crystallised with a tightly bound
inverse agonist, the exact state of the crystallised
complex is therefore open to debate. Another
problem is that when low-affinity agonists bind to
GPCRs, the agonist–receptor complex is often less
stable than the antagonist–receptor complex,20
making it more difficult to crystallise and produce
well-diffracting crystals. Therefore, to obtain the
structure of A2AR with an agonist bound, we have
extensively stabilised A2AR in a specific agonist-
binding conformation.
Conformational thermostabilisation is a strategy
used to engineer a membrane protein so that it is
sufficiently stable in short-chain detergent for
crystallisation and structure determination. The
strategy has been applied to the thermostabilisationof the β1AR,
21,22 the neurotensin receptor (NTS1)23
and A2AR.
24,25 In each instance, it was observed that,
if the selection for thermostabilising mutations was
performed with an antagonist, then the thermo-
stabilised mutant was preferentially in an antago-
nist-binding conformation; similarly, selection with
an agonist resulted in a receptor in the agonist-
binding conformation. Since there are distinctive
structural differences between the agonist- and the
antagonist-binding conformations, it is of little
surprise that different mutations are required to
stabilise the two different states.24 Stabilisation of
β1AR and A2AR in the antagonist-bound conforma-
tion allowed the crystallisation and structure deter-
mination of both receptors9 (Dore et al., unpublished
data). In contrast, thermostabilisation with agonists
has proved to be more difficult. In the case of NTS1,
the receptor was clearly thermostabilised, but on
purification, the receptor tended to aggregate.23 This
was ascribed to the stabilisation of the receptor
simultaneously in both a ligand-free conformation
and an agonist-bound conformation, thus resulting
in a mutant that can undergo changes in structure
upon ligand binding rather than being locked in a
single conformation. Here, we describe a modified
strategy for the stabilisation of A2AR in an agonist-
bound conformation. The stabilised receptor A2AR-
GL26 is now extremely stable in short-chain de-
tergents when the agonist 5'-N-ethylcarboxamido-
adenosine (NECA) is bound, and this has allowed its
purification in a monodisperse state and its subse-
quent crystallisation.Results
Identification of thermostabilising point
mutations in agonist-bound A2AR
The strategy used to identify thermostabilising
mutations involves creating a library of mutants
throughout the receptor where every amino acid
residue is changed to alanine or, if the residue is
already alanine, to leucine. Each mutant receptor is
then expressed and solubilised in detergent and has
its thermostability determined by measuring the
amount of receptor remaining after heating the
sample for 30 min at a given temperature. A
“thermostable” mutant in this context is therefore
used to describe a mutated receptor with a
decreased rate of unfolding, and the term thermo-
stable is not meant to imply anything with respect to
the thermodynamic properties of the receptor. In the
previously published method24 to select mutations
to produce a thermostable agonist-bound confor-
mation of A2AR, the thermostability was determined
by heating the detergent-solubilised receptor in the
absence of ligand, quenching on ice and then
300 Conformational Thermostabilisation of the A2A Receptorperforming a ligand binding assay using the agonist
[3H]NECA. Thermostabilising mutations were iden-
tified (Fig. 1) and combined to construct the mutant
A2AR-Rag23, which was 9 °C more thermostable
than the WT receptor. Although significant, this
small increase in stabilitywas considered insufficient
to guarantee success in structure determination. In
the interim, it was found that heating the receptor in
the thermostability assay in the presence of 3H-
labeled agonist produced mutants with a greater
increase in stability.23 Therefore, we rescreened all
315 point mutations made previously24 by heating
the detergent-solubilised mutants in the presence of
[3H]NECA (see Methods).
A necessary prerequisite to screen for [3H]NECA-
bound themostabilising mutants was to define an
optimum buffer to favour the formation of the
receptor–agonist complex. TheKd for NECA binding
to A2AR is reduced by high concentrations of(a)
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(b)detergent or NaCl, and the thermostability of [3H]
NECA-bound A2AR is similarly reduced under these
conditions.24 Therefore, the thermostability assay
developed contained low concentrations of n-dode-
cyl-β-D-maltopyranoside (DDM) and no NaCl. After
solubilisation in DDM, A2AR was bound to Ni
2+-
NTA resin, washed to reduce the DDM concentra-
tion and then eluted (see Methods). [3H]NECA was
then added to this partially purified sample, which
was then heated at various temperatures for 30 min
and quenched on ice, and the receptor-bound ligand
was separated from free ligand on a mini gel-
filtration column.26 This assay was used to define
the stability of theWT receptor (apparentTm) and for
the initial screen of all the Ala/Leu scanmutants.We
refer to this as the ligand plus format.23 The apparent
Tm is defined as the temperature at which 50% of the
solubilised receptor can still bind radioligand after a
30-min incubation.21,23,24 The apparent Tm for WTWL M YA I
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Fig. 1. Positions of thermostabi-
lising mutations in the primary
sequence of human A2AR. The
snake plot depicts the secondary
structure elements found in the
structure of A2AR, with the approx-
imate position of the lipid bilayer
shown ingrey. (a) Thermostabilising
mutations in the [3H]NECA-bound
conformation are shown in orange.
Mutations identified previously
from [3H]NECA assays performed
after heating the unliganded recep-
tor are shown in red.24 Mutations
thatwere selected by both assays are
blue. (b) The 16most thermostabilis-
ing mutations of the [3H]NECA-
bound conformation of A2AR were
re-assayed for thermostability in the
antagonist-bound conformation
using [3H]ZM241385 (Table 1): ma-
genta, mutants that did not bind
antagonist in this assay; green, mu-
tants that are less stable than WT
A2AR in the antagonist-bound con-
formation; and brown, mutants that
are more stable than WT in the
antagonist-bound conformation.
301Conformational Thermostabilisation of the A2A ReceptorA2AR using the [
3H]NECA thermostability assay
(see Methods) is 28.6±0.2 °C (n=8).
The library of Ala/Leu mutants made throughout
A2AR
24 was then expressed and solubilised in DDM,
and a single-point thermostability assay was per-
formed on each mutant by heating the [3H]NECA-
bound receptor at 28 °C for 30 min; the results of
these assays were compared to the thermostability
of theWT receptor. Out of the 315 mutants screened,
38 were found to increase the thermostability of [3H]
NECA-bound A2AR by a minimum of 40% and, in
addition, maintained a minimum expression level of
30%, both values compared toWTA2AR (Fig. 1). The
mutations thermostabilising [3H]NECA-bound
A2AR are, in general, different from the mutants
described previously that stabilise the ligand-free
A2AR selected with [
3H]NECA, although nine
mutations are common to both experiments (Fig.
1). The apparent Tmwas then determined for each of
the 38 mutants, and the 16 most thermostabilising
mutations (Table 1) were selected for further study.
The L48A mutant provided the greatest thermo-
stabilisation of the [3H]NECA-bound A2AR, confer-
ring a 13.6 °C improvement in stability (apparent Tm
of 42.2±0.75 °C; Fig. 2); the Ballesteros–Weinstein
numbers for all the amino acid residues discussed
are presented in Table 1. The remaining 15 mutants
improved the thermostability of [3H]NECA-bound
A2AR by 2–6 °C (Table 1). The 16 selected mutationsTable 1. Thermostability of A2AR mutants with either
agonist or antagonist bound
A2AR
mutation
Ballesteros–
Weinstein
Apparent Tm (°C)
Agonist Antagonist
[3H]
NECA ΔTm
[3H]
ZM241385 ΔTm
WT — 28.5 — 32 —
V12A 1.38 30.5 +2 n.d.a n.d.
S47A 2.45 31 +2.5 25.5 −6.5
L48A 2.46 42.5 +14 0b n.d.
A50L 2.48 31 +2.5 38.5 +6.5
A54L 2.52 33.5 +5 38 +6
V57A 2.55 34.5 +6 38 +6
F62A 2.60 31 +2.5 0 n.d.
T65A 2.63 33 +4.5 38 +6
F79A 3.27 31 +2.5 0 n.d.
F83A 3.31 30 +1.5 16.5 −15.5
Q89A 3.37 34.5 +6 26 −8
S90A 3.38 32 +3.5 32 0
A236L 6.38 31 +2.5 38 +6
I238A 6.40 31 +2.5 36 +4
F242A 6.44 31 +2.5 0 n.d.
V282A 7.47 30.5 +2 33 +1
Values were determined from a single thermostability curve with
values determined in triplicate with an estimated error of ±0.5 °C.
These values were used to give a rank order of thermostabilisa-
tion for the different mutants. For final values for WT A2AR and
L48A (GL0), please refer to Table 2.
a Not determined.
b No binding detected at antagonist concentration used.are highly clustered in the primary amino sequence
of A2AR, with 7 mutations in transmembrane region
(TM) 2, 4 in TM3 and 3 in TM6, with only 1 mutation
in TM1 and TM7 (Fig. 1).
The thermostabilising mutants were then tested
for their ability to thermostabilise A2AR when the
inverse agonist ZM241385 was bound. In theory, if a
mutation alters the equilibrium between R and R⁎ so
that the agonist-binding conformation R⁎ is prefer-
entially populated, then both the affinity for an
inverse agonist and the thermostability of the
receptor–inverse agonist complex could potentially
be compromised. The apparent Tm of [
3H]
ZM241385-bound A2AR was 32.0±0.1 °C (Table 1),
which is 3.5 °C more stable than that of [3H]NECA-
bound A2AR measured under identical conditions.
The 15 mutants that showed the highest thermosta-
bilities in the NECA-bound conformation were
tested for thermostability when ZM241385 was
bound. The results show that these 15 mutants can
be categorised into three classes (Table 1). The first
category contained mutants L48A, F62A, F79A and
F242A, which did not bind [3H]ZM241385 at 4 °C in
this experiment, suggesting a dramatic loss of
affinity (see below for ligand binding experiments),
and their thermostability with [3H]ZM241385
bound was not determined. The second category
contained mutants S47A, F83A and Q89A, which
stabilised the NECA-bound conformation and
destabilised the ZM241385-bound conformation.
The third group is composed of the remaining
mutations that stabilised both agonist- and inverse-
agonist-bound conformations (A50L, A54L, V57A,
T65A, S90A, A236L, I238A and V282A).
Combining mutants to make the optimally
thermostable agonist-bound receptor
A2AR-GL26
Given the unusually large increase in thermosta-
bility observed for A2AR-L48A, it was used as the
starting point for the construction of an optimally
stable agonist-binding receptor for structural stud-
ies, and it was renamed GL0. It has not usually
proved possible to predict whether the combination
of two thermostabilising point mutations will result
in an additive effect on the thermostability or
whether they will combine to destabilise the
receptor. Therefore, 13 of the remaining thermo-
stabilising point mutations were individually com-
bined with the L48A mutation (Table 2). Previous
experience of combining thermostabilising muta-
tions has shown that mutants close to each other in
the primary amino acid sequence were often not
additive;21,23,24 thus, the double mutants of L48A
with either S47A or A50L were not made. Each of
the double mutants was expressed, and its thermo-
stability was measured and compared to the pre-
dicted Tm [ΔTm for each single mutant (Table 2)
302 Conformational Thermostabilisation of the A2A Receptorsummed with the apparent Tm for WT A2AR]. Five
of the double mutants did not increase thermosta-
bility compared to the L48A single mutant (Fig. 2).
All of the remaining double mutants showed higher
thermostabilities compared to GL0, with the best
combination being L48A-Q89A (A2AR-GL10) with
an apparent Tm of 46.7±0.4 °C (Fig. 2). This strategy
was repeated using the double mutant GL10 as the25
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)starting point and adding the five mutations found
to be additive in the previous round. As previously
mentioned, mutating residues close to each other
often does not have an additive effect; thus, the S90A
mutation was not tested, and in addition, GL10
containing the mutation F83A could not be made.
One mutant showed an additive effect for the third
mutation, L48A-Q89A-T65A (A2AR-GL23), which
had an apparent Tm of 49.9±0.1 °C (Fig. 2). It is
interesting to note that all the mutations used to
construct GL23 are in TM2 and TM3 and that none
of the mutations in TM6 were additive with L48A
(Fig. 1 and Table 2).
To improve the thermostability of GL23 further,
we changed the detergent used in the thermostabil-
ity assay to a shorter-chain detergent, n-decyl-β-D-
maltopyranoside (DM). As expected, reducing the
size of the detergent decreased the stability of the
receptor, with A2AR-GL23 being 7.7 °C less stable in
DM than in DDM (Table 2). After a last round of
mutagenesis combining the additive mutants to
GL23, it was found that the addition of A54L to
make mutant GL26 yield the highest thermostabil-
ity. A2AR-GL26 displayed very good thermostability
in DM (apparent Tm of 44.5±0.8 °C) and also
excellent stability in a variety of other short-chain
detergents ideal for crystallography (Fig. 3). A2AR-
GL26 is 21.5 °C more stable than the WT receptor in
DM, which has an apparent Tm of 23 °C when
solubilised in this detergent.24
An alternative method for displaying the thermo-
stability of the various mutants is shown in Fig. 2c,
which relates the logarithm of the rate of inactiva-
tion of the receptor to the temperature (seeFig. 2. Thermostability of agonist-bound, DDM-solubi-
lised A2AR and thermostabilised mutants. (a) Additive
effect of thermostabilising mutations used to generate
A2AR-GL23. Predicted Tm values were calculated by
adding the ΔTm for each mutation (Table 1) to the
apparent Tm of WT A2AR. The broken line correlates
with perfect additivity. WTA2AR is represented by a black
diamond. The stabilities of the best thermostable mutants
containing one, two or three point mutations are labelled,
respectively, as follows: L48A (GL0), green diamond;
L48A-Q89A (GL10), dark-blue diamond; and L48A-Q89A-
T65A (GL23), red diamond. Other double mutants (light-
blue diamonds) and triple mutants (light-red diamonds)
that were less stable than the optimal combinations are
also shown. (b) Thermostability assays were performed on
receptors partially purified in 0.025% DDM and with [3H]
NECA bound; A2AR (black circles), apparent Tm of 28.6±
0.2 °C, n=8; GL0 (green squares), apparent Tm of 42.2±
1.0 °C, n=5; GL10 (blue triangles), apparent Tm of 46.7±
0.4 °C, n=3; and GL23 (red inverted triangles), apparent
Tm of 49.9±0.1 °C, n=2. (c) Stability of mutants compared
to WT A2AR based on t1/2 values calculated from (b) to
allow the improvement in stability of the mutants
compared to WT to be calculated: GL0, 49-fold; GL10,
136-fold; and GL23, 226-fold. The colour code is the same
as in (b).
Table 2. Combinations of mutants tested for thermostabilising the NECA-bound conformation of A2AR
Mutant
name A2AR mutations
Apparent Tm in DDM (°C)
Predicted Single measurementa Final valuesa
WT A2AR — — — — 28.6±0.2 (n=8)
Single mutant GL0 L48A 42.5 42.5 42.2±1.0 (n=5)
Double mutant GL1 L48A-V12A 45 45.5
GL4 L48A-A54L 47.5 46
GL5 L48A-V57A 48.5 41.5
GL6 L48A-F62A 45 45
GL7 L48A-T65A 47 45
GL8 L48A-F79A 45 45.5
GL9 L48A-F83A 44 43.5
GL10 L48A-Q89A 48.5 47.5 46.7±0.4 (n=3)
GL11 L48A-S90A 46 46
GL14 L48A-A236L 45 40.5
GL15 L48A-I238A 45 42.5
GL17 L48A-F242A 45 39.5
GL19 L48A-V282A 44.5 40
Triple mutant GL20 L48A-Q89A-V12A 49.5 46
GL21 L48A-Q89A-A54L 52 46
GL22 L48A-Q89A-F62A 49.5 45.5
GL24 L48A-Q89A-F79A 49.5 46
GL23 L48A-Q89A-T65A 51.5 50 49.9±0.1 (n=2)
Apparent Tm in DM (°C)
Predicted Single measurementa Final valuesa
Triple mutant GL23 L48A-Q89A-T65A 42.2±0.3 (n=2)
Quadruple mutant GL25 L48A-Q89A-T65A-A50L 46 44.5
GL26 L48A-Q89A-T65A-A54L 49 46 44.5±0.8 (n=3)
GL27 L48A-Q89A-T65A-F83A 44.5 44
GL29 L48A-Q89A-T65A- S263A 44.5 44.5
a Values were determined initially from a single thermostability curve, with measurements performed in triplicate, to find the most
thermostable mutants; replicate experiments were performed only for key mutants. Predicted Tm was calculated from the parental
experimental Tm value (single or double mutants) and the value of the ΔTm for the single mutant tested. Experimental measurements
were then compared with the predicted Tm and classified as (i) an additive effect when the experimental value is equal or similar to the
predicted Tm (±1.5 °C) and (ii) nonadditive when the experimental value is different from the predicted Tm. Quadruple mutants were
tested in DM.
303Conformational Thermostabilisation of the A2A ReceptorMethods). Provided that all the assays are per-
formed under identical conditions, this can be used
to estimate the factor by which a receptor is
stabilised compared to the WT receptor. Data
extracted from Fig. 2b were therefore replotted in
Fig. 2c and used to estimate that the rate of
unfolding of NECA-bound A2AR-GL23 was about
230 times slower than that of the NECA-bound WT
A2AR, implying a 230-fold improvement in the
thermostability of A2AR-GL23.
Pharmacological characterisation of
thermostabilised mutants
Three of the mutants (GL0, GL23 and GL26) were
transiently expressed in Chinese hamster ovary
(CHO) cells; the membranes were purified; and
competition binding analyses were performed using
agonists, an inverse agonist and antagonists, in
addition to saturation binding experiments per-
formed with [3H]NECA, to characterise how the
thermostabilising mutations have affected the con-
formation of A2AR (Table 3). The changes in pKi foreach mutant and all ligands tested are summarised
in Fig. 4. All the mutants bound the antagonists
CGS15943 and SCH58621, as well as the inverse
agonist ZM241385, more weakly (Fig. 4). In contrast,
there was no significant change in affinity for the
binding of all the agonists tested (NECA, ATL146e
and CGS21680) (Fig. 4) except that NECA bound
three times more tightly to GL23 than to WT A2AR
(Table 3). The data show that the major influence on
the conformation of the ultimate mutant A2AR-GL26
is from the L48A mutation in GL0. This single point
mutation accounted for 60–88% of the reduction in
antagonist affinity observed in GL26.
Purification of the thermostable mutant
A2AR-GL31
A2AR-GL26 was expressed using the baculovirus
expression system in insect cells to give about
2–3 mg/L of cell culture and then purified using a
two-step process, a Ni2+-NTA column followed by
size exclusion chromatography. However, purified
GL26 consisted of two species differing in molecular
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Fig. 3. Thermostability of the mutants GL23 and GL26.
(a) Thermostability of GL26 (red squares; apparent Tm of
44.5±0.8 °C, n=3) and GL23 (blue circles; apparent Tm of
42.2±0.3 °C, n=2) after partial purification in DM (0.17%),
both with [3H]NECA bound. (b) The thermostability of
GL26 with [3H]NECA bound was determined by partially
purifying the receptor in different detergents. GL26 was
solubilised in DM and immobilised on Ni2+-NTA agarose,
and then detergent exchange was performed. The results
are from a single experiment performed in triplicate, with
the final concentration of detergent indicated: 0.39%
decanoyl-N-hydroxyethylglucamide (pink inverted trian-
gles), apparent Tm of 42.3 °C; 0.17% decylmaltoside (red
squares), apparent Tm of 42.0 °C; 0.3% NG (green inverted
triangles), apparent Tm of 34.6 °C; 0.52% foscholine-10
(blue triangles), apparent Tm of 33.1 °C; 0.42% octylthio-
glucoside (orange circles), apparent Tm of 30.5 °C; 0.37%
polyoxyethylene C8E4 (pale blue circles), apparent Tm of
26.4 °C.
304 Conformational Thermostabilisation of the A2A Receptormass by about 3 kDa, which is consistent with only a
proportion of the receptor being N-glycosylated
(data not shown). Therefore, the predicted N-
glycosylation site Asn154 was mutated to Ala to
makeA2AR-GL31 (L48A-Q89A-T65A-A54L-N154A).
A2AR-GL31 was expressed in insect cells and
purified on a Ni2+-NTA column, followed by
size-exclusion chromatography (Fig. 5). Even if the
size-exclusion column was run using the detergentnonylglucoside (NG), purified A2AR-GL31 exhibited
a symmetrical peak, which is indicative of a highly
purified, monodisperse sample (Fig. 5). After con-
centration, one preparation yielded 1 mg of purified
receptor from a 2-L culture, and the receptor could be
concentrated up to 20 mg/mL without significant
aggregation. A2AR-GL31 bound to NECA produced
good-quality crystals that diffracted isotropically to
2.6 Å resolution (Lebon et al., unpublished data).Discussion
Conformational thermostabilisation of GPCRs has
proven to be a successful strategy for their structure
determination when the receptor is stabilised in the
antagonist state, with structures of both a β1AR
9
and an A2AR (Doré et al. unpublished data) with
antagonists bound having been determined. The
real value of the approach was recently highlighted
by the structures of β1AR bound to low-affinity
agonists.14 The other approaches that have also
given GPCR structures27 rely on increasing the
hydrophilic area of the receptor by binding an
antibody fragment and/or with a T4L fusion and on
the thermostabilisation of the receptor by formation
of a complex with a high-affinity ligand with a slow
off-rate.8,28 In the case of A2AR, we would like to
determine its structure bound to its natural agonist,
adenosine; thus, thermostabilisation seemed to be
the logical approach to take. Two different thermo-
stabilisation procedures have been developed pre-
viously for stabilising a GPCR in an agonist-bound
conformation, and these gave rise to thermostable
mutants A2AR-Rag23
24 and NTS1-7m,23 but in both
cases, the degree of thermostabilisation attained was
probably too small to guarantee the formation of
well-diffracting crystals. Here, we describe another
strategy that produced the mutant A2AR-GL26,
which is highly thermostable and has already been
purified and crystallised. The two significant
changes introduced here in relation to previous
procedures were, firstly, the use of [3H]NECA-
bound A2AR in the thermostability assay and,
secondly, the removal of the requirement for
simultaneous stabilisation of the unliganded and
NECA-bound conformations. The resulting mutant,
A2AR-GL26, is similar in stability upon detergent
solubilisation to native rhodopsin29 or β1AR-m23,
21
both of which have been crystallised and their
structures determined to high resolution.
Four mutations were required to thermostabilise
A2aR in the agonist-bound conformation. The
single mutation with the greatest thermostabilising
effect was L48A, which increased the stability of
NECA-bound A2AR by 13.6 °C. The L48A mutant
was therefore an obvious candidate to start the
thermostabilisation of the A2A NECA-bound con-
formation. The strategy was to make a series of
Table 3. Comparison of affinities of agonist and antagonist binding to A2AR and thermostable mutants
pKi (−Log M)
WT GL0 GL23 GL26
Agonist NECA 7.82±0.20 7.94±0.06 8.43±0.07⁎ 8.13±0.11
ATL146e 7.95±0.17 7.96±0.01 8.25±0.01 7.85±0.08
CGS21680 6.94±0.11 6.89±0.05 7.24±0.19 6.77±0.06
Antagonist ZM241385 9.22±0.04 7.65±0.17⁎⁎⁎ 6.89±0.06⁎⁎⁎ 6.67±0.08⁎⁎⁎
CGS15943 9.68±0.11 7.91±0.06⁎⁎⁎ 7.49±0.10⁎⁎⁎ 7.17±0.08⁎⁎⁎
SCH58621 8.92±0.17 6.97±0.06⁎⁎⁎ 7.10±0.12⁎⁎⁎ 4.61±0.20⁎⁎⁎
Competition experiments were performed by displacement of [3H]NECA from receptors transiently expressed in CHO cells. The pKi
values are the mean of three independent experiments performed in triplicate±standard error of the mean. pKi values were calculated
from the IC50 using the Cheng–Prusoff equation and the following values forKd (nM) for [
3H]NECA:WT, 13.45±0.44; GL0, 6.39±0.59⁎⁎⁎;
GL23, 4.65±0.67⁎⁎⁎; and GL26, 6.33±0.66⁎⁎⁎. P values were determined using a one-way ANOVA with Dunnett's post-hoc test:
⁎, Pb0.05; ⁎⁎⁎, Pb0.001 with respect to the WT A2AR.
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ing mutants to L48A, testing their thermostability,
picking the most thermostable double mutant and
then adding the next best single thermostabilising
mutation. At each stage, only those single muta-
tions that gave a clear additive increase in
thermostability were tested in the next round.
Out of 13 double mutants constructed and tested
for their thermostability, the L48A-Q89A mutant
had the highest thermostability, which was only
slightly lower than the Tm predicted by adding the
ΔTm for Q89A to the Tm for L89A. In a similar
fashion, T65A was found to further thermostabilise
the receptor to make the triple mutant GL23
(L48A-Q89A-T65A) with an apparent Tm of 50 °C
in DDM. We have sometimes found that the
measurement of apparent Tm at high temperatures
may be less accurate than desired due to non-
specific protein aggregation in the sample; there-
fore, we decided to carry out one more round of
thermostabilisation in DM. As expected, the
thermostability of GL23 was lower in DM than
in DDM (Fig. 3). Among the five mutations tested,
the best additive effect was observed for the A54L
mutant. The final mutant GL26 displays an
apparent Tm of 44.5 °C in 0.15% DM, which is
similar to that observed for the thermostable
mutant β1AR-m23 (apparent Tm of 48 °C).
21
A2AR-GL26 also displayed considerable stability
in relatively harsh detergents such as foscholine-10
(FC10), decanoyl-N-hydroxyethylglucamide and
n-octyl-β-D-thioglucopyranoside, which have been
used previously to crystallise β1AR-m23.
30
In previous thermostabilisation experiments,
each receptor was stabilised in a particular
conformation depending on whether an agonist
or an antagonist was used for the selection of
thermostable mutants. The conformation of A2AR-
GL26 was therefore assessed by performing ligand
binding assays using both agonists and antago-
nists. The binding affinities for the inverse agonist
ZM241385 and the antagonist CGS15943 were
reduced by 320-fold, whereas the only statisticallysignificant change in agonist binding affinity was
observed for NECA (3-fold increase). The affinities
for ATL146e and CGS21680 remained similar to
those of WT A2AR. None of the mutations used to
thermostabilise A2AR-GL26 are in the ligand
binding pocket, which suggests that they acted
by affecting the global conformation of the
receptor. It is not possible to define exactly
which conformational state A2AR-GL26 is in,
except by determining its structure, but the
binding data are consistent with A2AR-GL26
being in an agonist-binding conformation. How-
ever, it is very unlikely that the conformation is
identical with the fully activated state because it
would then be expected that agonist affinity would
be increased by a factor of 15–40 or more.31,32 It is
thus anticipated that the receptor will represent a
conformation along the activation pathway, be-
tween the R state and the R⁎ state.
Analysis of the ZM241385-bound structure of
A2AR
8 showed that none of the thermostabilising
mutants in A2AR-GL26 make direct contact to the
ligand (Fig. 6). It is therefore likely that the
introduction of the four thermostabilising mutations
L48A, T65A, Q89A and A54L has induced a
conformational change in the receptor, and the
binding data support the view that the mutant is
in an agonist-binding conformation between R and
R⁎. The single biggest effect on ligand binding was
seen for the mutation L48A2.46 (superscript refers to
the Ballesteros–Weinstein numbering system33)
with a 2-fold increase in the affinity for the agonist
NECA and a 50-fold decrease in affinity for the
inverse agonist ZM241385. In the entire GPCR
family, Leu2.46 is one of the most conserved residues
in TM2 (approximately L 96%, M 2%, I 1.5% and V/
T 0.5%). When mutated to alanine, Leu2.46 displays
constitutive activity in rhodopsin34 and the thyro-
tropin receptor.35 The side chain of Leu482.46 is
located near the cytoplasmic end of TM2 and
oriented towards the core of the receptor helix
bundle close to the NPXXY motif in TM7, which is
composed of the highly conserved residues Asn7.49,
306 Conformational Thermostabilisation of the A2A ReceptorPro7.50 and Tyr7.53. Leu2.46 has been described as
being involved in a hydrophobic interaction with
Asn7.49, which may constrain the receptor in an
inactive conformation,35 and was suggested to
stabilise the ground state of rhodopsin.34 The
Q89A mutation was previously reported to increase(b)
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Fig. 5. Purification of A2AR-GL31. The unglycosylated
mutant of A2AR-GL26, A2AR-GL31, was expressed in
insect cells using a recombinant baculovirus and purified
on Ni2+-NTA. The receptor was further purified by size-
exclusion chromatography (A280 trace is shown; void (V0)
and total (VT) column volumes are indicated); this gave a
symmetrical peak, which indicated that the preparation
was monodisperse and homogenous. A Coomassie-blue-
stained SDS-polyacrylamide gel (inset) showed that A2AR-
GL31 represented a single band on the gel (left-hand lane)
that was sufficiently pure for crystallisation (molecular
weight markers are shown on the right).the affinity of agonists and decrease the affinity for
antagonists, perhaps through an indirect effect on
the receptor,36 which we also observed here (Fig. 4).
In the crystal structure of A2AR bound to ZM241385,
both T65A and A54L are located in TM2 facing the
lipid bilayer; thus, it is unclear why these mutations
are thermostabilising.
The rationale for thermostabilising membrane
proteins is to allow the use of short-chain detergents
during both purification and crystallisation, which
will improve the probability of success in obtaining
well-diffracting crystals that are suitable for struc-
ture determination.37 Therefore, the success of any
thermostabilisation procedure should be apparent
during purification of the mutated receptor because
it should not aggregate even if relatively harshFig. 4. Affinities of agonists and antagonists for A2AR
and the thermostabilised mutants. (a and b) Competition
binding experiments were performed by measuring the
displacement of [3H]NECA bound to receptors in CHO
cell membranes. Experiments were performed using three
agonists (NECA, ATL146e and CGS21680) and two
antagonists (CGS15943 and SCH58621) and the inverse
agonist ZM241385 with example curves shown for
ZM241385 (a) and NECA (b); WT A2AR, black circles;
GL0, green squares; GL23, blue triangles; and GL26, red
inverted triangles. Full data are shown in Table 3. (c) The
differences in affinities (ΔpKi) between the WT A2AR and
each of the mutants for the ligands tested were calculated
from the pKi values determined in Table 3; GL0, green;
GL23, blue; and GL26, red.
Fig. 6. Positions of the thermostabilising mutations in
the antagonist-bound A2A structure. The structure of
A2AR-StaR2 (Protein Data Bank code 3PWH) thermosta-
bilised in an antagonist-bound conformation is shown in
rainbow colouration with the N-terminus and C-terminus
labelled (N and C, respectively) and the bound antagonist
ZM241385 depicted as a space-filling model (C, pink: N,
blue; and O, red). The four amino acid residues mutated in
A2AR to generate the thermostable mutant GL26 (L48A,
Q89A, T65A and A54L) are depicted as space-filling
models (dark grey). Note that the amino acid sequence
shown is that of A2AR-StaR2, which also contains the
A54L thermostabilising mutation,25 whereas Leu48, Gln89
and Thr65 are identical with WT A2AR.
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GL26 showed that the receptor was present as both
an unglycosylated and an N-glycosylated product
(results not shown); thus, the additional mutation
N154A was introduced into A2AR-GL26 to make the
non-glycosylated mutant A2AR-GL31. This was
subsequently purified in NG, and the product was
monodisperse and pure, showing that the protein
was ideal for crystallography. Indeed, crystals were
obtained relatively easily and have been improved
to diffract to better than 2.6 Å resolution; the
structure of A2AR-GL31 is currently under refine-
ment. Thus, the simplified thermostabilisation strat-
egy presented here for stabilising the agonist-boundform of GPCRs was successful and should be
equally applicable to other GPCRs.Methods
Expression of adenosine A2AR point mutants
in Escherichia coli
The library of Ala/Leu scan mutants in the receptor
A2aR-(2–316) was expressed from plasmid pRG/III-hs-
MBP in E. coli strain DH5α as previously described.24 Cells
were grown at 37 °C in 2-L flasks containing 500 mL of 2×
tryptone–yeast medium supplemented with ampicillin
(100 μg/mL) and glucose (0.2% w/v). At an OD600 of 0.7,
IPTG and theophylline were added at final concentrations
of 0.5 mM and 100 μM, respectively, and the temperature
was reduced to 20 °C. After 22 to 24 h, cells were harvested
in aliquots of 14 mL, centrifuged (30 min, 5000g) and
stored at −20 °C.Solubilisation and partial purification
of adenosine A2AR mutants for
thermostability assays
An aliquot of E. coli cells (14 mL) was thawed on ice and
resupended in 500 μL of buffer A [50 mM Tris–HCl
(pH 7.4), 0.4 M NaCl, 250 μg/mL lysozyme (Sigma) and
1 mg/mL DNase I (Sigma), supplemented with complete
ethylenediaminetetraacetic acid (EDTA)-free Protease
inhibitor cocktail (Roche)] and incubated for 1 h at 4 °C.
Samples were then sonicated for 1 min at 4 °C using a cup-
horn sonicator. The receptors were solubilised by adding
1% DDM and incubated for 1 h at 4 °C. Insoluble material
was removed by centrifugation (5 min, 13,000g, 4 °C). The
solubilised receptors were partially purified with Ni-NTA
agarose (Qiagen). Agarose beads (300 μL) pre-equilibrated
in buffer A were added to 700 μL of solubilised receptor.
To reduce the detergent concentration by dilution, we
added a solution of 50 mM Tris–HCl, pH 7.4, and 0.4 M
NaCl to a final volume of 2 mL. After 2 h of incubation at
4 °C, samples were centrifuged (13,000g, 10 s, 4 °C),
washed three times in buffer B (25 mMHepes, pH 7.4, and
0.025% DDM) and then eluted in buffer B supplemented
with 50 mM histidine for 30 min at 4 °C. The supernatant
was used directly in radioligand binding assay.Radioligand binding assay and thermostability
assay for detergent-solubilised receptors
Solubilised receptor (108 μL) was mixed with 12 μL of
4 μM [3H]NECA (final concentration of 400 nM) or 12 μL
of 1 μM [3H]ZM241385 (final concentration of 100 nM).
Radioligand concentrations used were approximately
10-fold the Kd value. The sample was incubated for 45 min
at 4 °C, then 30 min at the specified temperature and then
30 min at 4 °C. Receptor-bound and free radioligands were
separated as previously described on mini gel-filtration
columns.26 Receptor-bound ligands were transferred to a
96-well plate (PerkinElmer) and mixed with 200 μL of
Optiphase supermix (PerkinElmer). The bound 3H-labeled
308 Conformational Thermostabilisation of the A2A Receptorligand was determined using a 1450 Microbeta Trilux
counter (1 min per sample).Mammalian cell culture and receptor expression
CHO cells were maintained in culture in Dulbecco's
modified Eagle's medium/HAMs F12 media containing
10% fetal bovine serum (FBS). Cells were transfected with
either WT adenosine A2AR or a stabilised receptor
construct using GeneJuice according to the manufacturer's
instructions. After 48 h post-transfection, cells were
harvested by scraping and centrifuged (200g, 5 min,
4 °C). The supernatant was removed, and the pellet was
resuspended in 10 mL of 20 mM Hepes buffer+10 mM
EDTA buffer (pH 7.4). The membrane suspension was
homogenised (10 s, 20,500 rpm) and centrifuged (200g,
15 min, 4 °C). The supernatant was collected, the pellet
was resuspended in 10 mL of Hepes/EDTA buffer and the
solution was homogenised and centrifuged as described
before. The collected supernatant was centrifuged (30 min,
40,000g, 4 °C). Pellets were resuspended in 20 mM Hepes,
pH 7.4, and 0.1 mM EDTA to a concentration of 1 mg/mL
and stored at −80 °C until further use.Ligand binding assays, saturation and
competition binding experiment
Membranes from CHO cells transiently expressing
receptors (10–15 μg/well) were assessed using competi-
tion [3H]NECA binding in buffer containing 50 mM Tris–
HCl (pH 7.4). Nonspecific bindingwas defined using 1 μM
CGS21680. After 1 h of incubation at 25 °C, assays were
terminated by filtration through 96-well GF/B filter plates
presoaked with 0.1% polyethyleneimine and washed with
5×0.5 mL water. Plates were dried, and bound ligand was
measured using a Microbeta counter. Inhibition curves
were fitted to a four-parameter logistic equation to
determine IC50 values, which were converted into Ki
values using Kd values determined by saturation binding
and the [3H]NECA concentration (∼10 nM).Purification of NECA-bound A2AR-GL31
Receptors were expressed with the baculovirus system
using cells derived from Trichoplusia ni (High 5™) and the
vector pBacPAK8 (Invitrogen). Insect cells were grown in
suspension in a maximum volume of 500 mL in 2-L roller
bottles (Corning) at 27 °C with shaking at 150 rpm. Sf9
cells were grown in TNM-FHmedium supplemented with
10% FBS, and Tni cells were grown in EXcell 405 medium
supplemented with 5% FBS (heat inactivated); all media
were supplemented with 1% lipids (Invitrogen). The GL31
construct was inserted into plasmid pBacPAK8 using the
restriction enzyme BamHI/XbaI. Sf9 cells were used to
generate the first virus passages and to obtain second- and
third-passage high-titre virus stocks. Tni cells were grown
to 2×106 to 2.5×106 cells/L, diluted in a 1:1 volume ratio
with fresh media and infected with the recombinant
baculovirus. Cells were harvested 72 h postinfection,
resuspended in 25 mM Hepes, pH 7.4, and 1× protease
inhibitor cocktail and snap-frozen in liquid N2.All protein purification steps were performed at 4 °C.
Frozen cell pellets equivalent to 2 L of cell culture were
thawed and resuspended at room temperature in 25 mM
Hepes (pH 7.4), EDTA 1 mM, PMSF (0.5 mM), pepstatin
(1 μg/mL) and leupeptin (1 μg/mL) or 1× protease
inhibitor cocktail to give a final volume of 360 mL. The
cells were centrifuged (120,000g, 2 h, 4 °C) to pellet the
washed cells and membranes, the supernatant was
carefully removed and the pellet was resupended in
240 mL of the same buffer. Cells were homogenised using
a Polytron (12,000 rpm, 2×15 s on ice) and centrifuged to
pellet the membranes (45,000g, 2 h, 4 °C). The pellet was
resuspended in 25 mM Hepes (pH 7.4), PMSF (0.5 mM),
pepstatin (1 μg/mL) and leupeptin (1 μg/mL) or 1×
protease inhibitor cocktail, homogenised using a Polytron
(12,000 rpm, 2×15 s on ice) and snap-frozen in liquid N2.
Membranes were thawed at room temperature, diluted
with 25 mM Hepes (pH 7.4), PMSF (0.5 mM), pepstatin
(1μg/mL) and leupeptin (1 μg/mL) or 1× protease inhibitor
cocktail (100 mL). Membranes were pre-incubated
with NECA at 100 μM for 45 min before solubilisation.
Receptors were solubilised by adding DM and NaCl to
give final concentrations of 1.5% and 0.3 M, respectively,
followed by centrifugation (120,000g, 45 min, 4 °C). The
solubilised receptor sample was then filtered through a
0.22-μm filter (Millipore) and applied at 0.3 mL/min to
a 5-mL Ni-NTA superflow cartridge (Qiagen) pre-
equilibrated with buffer [25 mM Hepes (pH 7.4), 0.1 M
NaCl, 100 μM NECA, 0.15% DM and 2.5 mM imidazole].
The columnwas washed (1 mL/min) with the same buffer
supplementedwith 10, 40 or 80mM imidazole for 5, 10 and
5 column volumes, respectively, and then eluted with
5 column volumes of elution buffer [25 mM Hepes
(pH 7.4), 0.1 M NaCl, 100 μM NECA, 0.15% DM and
250 mM imidazole]. The eluted receptor was mixed with
tobacco etch virus protease to cleave the tag for 4–6 h at
4 °C. After cleavage, 14–16 mL of the pooled fractions was
concentrated to 2 mL using an Amicon-ultra spin
concentrator (Ultracel-50K; Millipore) and loaded onto a
PD-10 column (GE Healthcare) in order to remove the
imidazole. A negative purification was used to remove the
tobacco etch virus protease by loading the sample in batch
onto 5 mL Ni-NTA (Qiagen) pre-equilibrated in 25 mM
Hepes (pH 7.4), 0.1MNaCl, 100 μMNECA, 0.15%DMand
40 mM imidazole and incubated for 30 min. The resin was
spun down, and the supernatant containing the receptor
was removed. For detergent exchange (into, e.g., 0.35%
NG), the sample (5.5–6 mL) was concentrated down to
0.5 mL using an Amicon-ultra concentrator (Ultracel-50K;
Millipore), diluted 10-fold in 25 mMHepes (pH 7.4), 0.1 M
NaCl, 100 μM NECA and 0.35% NG and concentrated
down again to 0.3 to 0.5 mL. The protein sample was
applied to a 10/30 S200 size-exclusion column pre-
equilibrated in 25 mM Hepes (pH 7.4), 0.1 M NaCl,
100 μM NECA and 0.35% NG and run at 0.5 mL/min.
Protein determination was performed using the amido
black assay.38Determination of receptor half-life (t1/2) using
the Arrhenius law
For all the thermostabilisation studies carried out in our
laboratory, the apparent Tm is the temperature for which
50% of the solubilised receptor remains folded after 30 min
309Conformational Thermostabilisation of the A2A Receptorof incubation. The rate constant of the protein denaturation
is a function of the temperature, and consequently, thermal
denaturation of a protein can be compared to a chemical
reaction for which the rate of the reaction is dependant on
the temperature. Arrhenius established that any chemical
reaction is temperature dependant. We used a simplified
version of the Arrhenius law to estimate the t1/2 of A2AR:
A=A0exp(−0.693× t/t1/2), in which A is the total sample
activity,A0 is the activity for a defined temperature, t is the
experimental time used for heating the sample and t1/2 is
the half-life of A2AR bound to its agonist NECA. From the
experimentally determined Tm curves, the values t and A
were selected as being the slope of the curve, defining a
window around the Tm value, which represents the linear
part of the curve, from 26.5 °C to 32 °C for the WT, from
39 °C to 45 °C for GL0, from 44 °C to 50 °C for GL10 and
from 47.5 °C to 53 °C for GL23. The referencemeasurement
representing the total binding activity of the sampleA0 was
considered to be measured at 4 °C. From the graphical
representation t=Log10(t1/2) (Fig. 2c), we could extract a
half-life for each construct at any temperature to define the
improvement in stability of the various mutants compared
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